Core Viewpoint - The financial performance of 基蛋生物 (603387) for the first half of 2025 shows a significant decline in revenue and net profit compared to the previous year, indicating challenges in the domestic market and potential issues with accounts receivable management [1][6]. Financial Performance Summary - Total revenue for the first half of 2025 was 513 million yuan, a decrease of 17.0% year-on-year [1]. - Net profit attributable to shareholders was 109 million yuan, down 25.88% from the previous year [1]. - The gross margin was 69.36%, slightly up by 0.14% year-on-year, while the net margin fell to 20.05%, a decrease of 17.95% [1]. - The total of selling, administrative, and financial expenses was 146 million yuan, accounting for 28.39% of revenue, a slight decrease of 0.92% year-on-year [1]. - Earnings per share decreased to 0.21 yuan, down 27.59% year-on-year [1]. Accounts Receivable and Cash Flow - Accounts receivable amounted to 786 million yuan, representing 177.8% of the latest annual net profit, indicating a high level of receivables relative to profit [1][14]. - Operating cash flow per share was 0.29 yuan, down 9.74% year-on-year, reflecting reduced cash inflows from sales [1][10]. Changes in Financial Items - Significant changes in financial items included a 15.79% increase in trading financial assets due to an increase in investment bank financial products [2]. - A 42.15% decrease in accounts receivable financing was noted, attributed to a reduction in bank acceptance bills [2]. - Short-term borrowings increased by 18.87%, indicating a rise in short-term debt [3]. Cost Management - Operating costs decreased by 17.26%, in line with the drop in revenue [7]. - Sales expenses fell by 22.91% due to cost control measures, including reductions in travel and promotional expenses [7]. - Research and development expenses decreased by 9.66%, reflecting improved management and optimization of R&D projects [9]. Business Model and Market Position - The company's performance is primarily driven by R&D and marketing efforts, necessitating a thorough examination of the underlying factors influencing these drivers [13]. - The return on invested capital (ROIC) for the previous year was 5.96%, indicating average capital returns, with a historical median ROIC of 21.97% since its listing [12].

Group 1 - The company reported a revenue of 513 million yuan for the first half of 2025, representing a year-on-year decline of 17.00% [1] - The net profit attributable to the parent company was 109 million yuan, down 25.88% year-on-year [1] - The net profit excluding non-recurring items was 93.23 million yuan, reflecting a year-on-year decrease of 28.52% [1]

Group 1 - The company,基蛋生物, announced the resignation of its securities representative,谢玉鑫, due to job changes, and appointed王娇 as the new representative [1] - The company will hold its fourth board meeting on August 29, 2025, to review the appointment of the new securities representative [1] - For the year 2024, the company's revenue composition is 100% from in vitro diagnostics [1] Group 2 - As of the report, the market capitalization of基蛋生物 is 4.3 billion yuan [1]

Core Viewpoint - Getein Biotech, Inc. reported a decline in revenue and net profit for the first half of 2025, with a focus on maintaining a strong position in the in vitro diagnostics (IVD) market despite challenges [1][2]. Financial Performance - Revenue for the first half of 2025 was approximately RMB 512.69 million, a decrease of 17% compared to RMB 617.67 million in the same period last year [2]. - Total profit for the period was RMB 110.53 million, down 33.49% from RMB 166.18 million year-on-year [2]. - Net profit attributable to shareholders was RMB 108.81 million, reflecting a 25.88% decline from RMB 146.81 million in the previous year [2]. - The company proposed a cash dividend of RMB 0.9 per 10 shares, amounting to a total distribution of approximately RMB 45.64 million, which represents 41.95% of the net profit for the period [1]. Industry Overview - The global IVD market is projected to reach USD 109.2 billion in 2024 and is expected to grow significantly, driven by factors such as policy support, aging populations, and rising chronic disease rates [4][5]. - In China, the IVD market has experienced rapid growth due to increased healthcare demand, improved medical insurance coverage, and advancements in domestic technology [5][6]. - The POCT segment is one of the fastest-growing areas in the IVD market, driven by the convenience and speed of testing, with significant potential for future growth [6]. Company Strategy and Product Development - The company has established eight major technology platforms, including POCT, chemiluminescence, biochemical detection, and molecular detection, to meet clinical needs [7][9]. - Getein has transitioned from a single POCT product line to a diverse range of products, including high-throughput and automated solutions for various healthcare settings [9][10]. - The company is actively expanding its market presence both domestically and internationally, with a focus on building a robust sales network through partnerships with over 3,000 distributors [12][13]. Regulatory and Market Position - As of June 30, 2025, the company held a total of 3,245 product registration certificates, with 460 of these being domestic [11][12]. - Getein's products are now available in 67 countries and regions, with a total of 2,785 product import licenses obtained [12][11]. - The company is committed to maintaining high-quality standards in production, adhering to ISO13485 quality management systems, and ensuring compliance with medical device regulations [14][15].

Core Viewpoint - The report highlights the financial performance and operational developments of Getein Biotech, indicating a decrease in revenue and profit while emphasizing ongoing innovation and market expansion efforts [1][2][3]. Financial Performance - Total assets at the end of the reporting period reached approximately CNY 3.91 billion, an increase of 5.47% compared to the previous year [3]. - Operating revenue for the first half of 2025 was approximately CNY 512.69 million, representing a decrease of 17.00% year-on-year [3]. - Total profit amounted to approximately CNY 110.53 million, down 33.49% from the previous year [3]. - Net profit attributable to shareholders was approximately CNY 93.23 million, a decrease of 28.52% year-on-year [3]. - The cash dividend proposed is CNY 0.9 per 10 shares, accounting for 41.95% of the net profit for the first half of 2025 [2]. Business Operations - The company continues to focus on its core business, with the chemical luminescence segment generating revenue of approximately CNY 150 million, a year-on-year increase of 10.64% [7]. - The company has developed 104 chemical luminescence detection projects, achieving full coverage of common clinical diseases [7]. - The Metis600 and Metis7000 automated biochemical immunoassay lines have been upgraded to enhance efficiency and adaptability for clinical needs [8][9]. - The GN7000/GN7120 automatic nucleic acid amplification analyzers have been launched, achieving significant market penetration with nearly 60 units installed since December 2024 [10]. Innovation and R&D - The company holds a total of 383 patents, including 57 invention patents, indicating a strong focus on innovation [11]. - The introduction of self-developed raw materials has increased the self-sufficiency rate of key materials to over 90% [13]. - The company is committed to expanding its product line and enhancing the performance of existing products to reduce production costs [13]. International Expansion - The company has established product entry permits in 67 countries, with nearly 2800 products approved for import [14]. - The international marketing strategy includes both online and offline channels, enhancing brand recognition and market share [14]. - The company has participated in exhibitions in Dubai and Nigeria, further promoting its global presence [14]. Quality Management - The company adheres to strict quality management standards, aligning with international regulations and certifications [15]. - A comprehensive quality management system has been established, covering all stages from R&D to delivery [15]. - The company has conducted multiple training sessions to enhance the skills of its service team, ensuring high customer satisfaction [16].

证券代码：603387 证券简称：基蛋生物 公告编号：2025-031 ? 每股分配比例：向全体股东每10股派发人民币0.9元（含税）。 ? 本次利润分配以实施权益分派股权登记日总股本数为基数，具体日期将 在权益分派实施公告中明确。在实施权益分派的股权登记日前公司总股本发生变 动的，拟维持分配总额不变，相应调整每股分配比例，并将另行公告具体调整情 况。 一、利润分配方案内容 截至 2025 年 6 月 30 日，公司合并报表归属于上市公司股东的净利润为人民 币 108,808,763.23 元 ， 母 公 司 报 表 中 期 末 未 分 配 利 润 为 人 民 币 每 10 股派发人民币 0.9 元（含税），以第四届董事会第七次会议召开日的前一个 交易日（即 2025 年 8 月 28 日）总股本 507,153,517 股进行计算，公司共需派发 现金股利 45,643,816.53 元。此次现金分红占 2025 年半年度合并报表归属于上 市公司股东的净利润比例为 41.95%。 如在实施权益分派的股权登记日前公司总股本发生变动的，拟维持分配总额 不变，相应调整每股分配比例，并将另行公告具体调整情况。 根据公 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-030 基蛋生物科技股份有限公司 第四届监事会第七次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届监事会第七次会议的通知 已于2025年8月18日以电子邮件的方式发出，通知了全体监事和其他列席人员。公司本 次监事会会议于2025年8月29日以现场及通讯表决方式召开。会议应出席监事3人，实际 出席监事3人。会议由监事会主席李靖召集和主持，公司董事会秘书和财务负责人列席 了本次监事会会议。本次会议的召开符合《中华人民共和国公司法》和《基蛋生物科技 股份有限公司章程》及有关法律法规的规定，会议决议合法有效。 二、监事会会议审议情况 （一）审议并通过《关于公司〈2025年半年度报告〉及其摘要的议案》 公司根据2025年半年度的实际经营情况和财务状况，依照有关规定编制《2025年半 年度报告》及其摘要。 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)及《上 ...

证券代码：603387 证券简称：基蛋生物 公告编号：2025-029 基蛋生物科技股份有限公司 第四届董事会第七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 基蛋生物科技股份有限公司（以下简称"公司"）第四届董事会第七次会议的通知 已于 2025 年 8 月 18 日以电子邮件形式向全体董事发出。本次会议于 2025 年 8 月 29 日 以现场及通讯表决方式召开。会议应出席董事 9 人，实际出席董事 9 人。本次会议由董 事长苏恩本先生主持，公司全体监事和高级管理人员列席了本次会议。本次会议的召开 符合《中华人民共和国公司法》和《基蛋生物科技股份有限公司章程》及有关法律法规 的规定，会议决议合法有效。 二、董事会会议审议情况 （一）审议并通过《关于公司〈2025 年半年度报告〉及其摘要的议案》 公司根据 2025 年半年度的实际经营情况和财务状况，依照有关规定编制《2025 年 半年度报告》及其摘要。董事会审核后认为公司编制的 2025 年半年度报告及其摘要， 可以全面、客观、 ...

Meeting Information - The first extraordinary general meeting of shareholders for 2025 will be held on September 15, 2025, at 14:00 [1] - The meeting will take place at the fourth-floor conference room of the company located at No. 9, Bofu Road, Yangtze River Industrial Development Zone, Liuhe District, Nanjing [1] - Voting will be conducted through a combination of on-site and online methods using the Shanghai Stock Exchange's network voting system [1] Voting Procedures - Shareholders can vote via the Shanghai Stock Exchange network voting system from 9:15 to 15:00 on the day of the meeting [1][2] - Specific voting times include trading hours: 9:15-9:25, 9:30-11:30, and 13:00-15:00 [1] - Shareholders holding multiple accounts can aggregate their voting rights across all accounts [4] Shareholder Participation - Only shareholders registered by the close of trading on September 8, 2025, are eligible to attend the meeting [6] - Shareholders can appoint proxies to attend and vote on their behalf, with specific documentation required for both representatives and proxies [5][6] Notification Services - The company will utilize a reminder service provided by Shanghai Stock Exchange Information Network Co., Ltd. to notify shareholders about the meeting and voting [3][4] - Notifications will be sent via smart SMS to ensure that small and medium investors can participate [3]

Group 1 - The company held its fourth board meeting on August 29, 2025, where it approved the proposal to revise and establish corporate governance-related systems [1] - The revisions and new systems are aimed at standardizing company operations in accordance with the Company Law and Securities Law of the People's Republic of China, as well as the revised Articles of Association [1] - The proposed systems will be submitted for shareholder meeting approval, with the first seven items requiring such approval [1][2] Group 2 - The company has disclosed the details of the revised and newly established governance systems on the Shanghai Stock Exchange website and in the Shanghai Securities Journal [1]